Alpha Score of 53 reflects moderate overall profile with moderate momentum, moderate value, weak quality, moderate sentiment.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Maverick Capital Lee Ainslie | 1.14M | $101.94M | NEW |
| Marshall Wace | 752K | $67.12M | NEW |
| Point72 Steve Cohen | 409K | $36.52M | NEW |
| Soros Fund Management George Soros (founder) | 220K | $19.64M | NEW |
| Renaissance Technologies Jim Simons (founder) | 168K | $15.03M | NEW |
| Citadel Ken Griffin | 122K | $10.90M | NEW |
| D.E. Shaw David Shaw | 31K | $2.73M | NEW |
SomniGroup International Inc. is a key player in the global pharmaceutical and healthcare industry. Its primary function is to research, develop, and market innovative healthcare solutions aimed at improving health outcomes worldwide. SomniGroup is well-regarded for its development of life-saving medications and therapies focused on chronic and rare diseases, as well as its cutting-edge contributions to vaccine technology. The company has a diverse portfolio that includes over-the-counter pharmaceuticals, prescription drugs, and biotech products, serving a broad range of sectors from hospitals and clinics to retail pharmacies and healthcare providers. Headquartered strategically to leverage global supply chains, SomniGroup International Inc. plays a vital role in advancing medical science and enhancing public healthcare systems. By continually investing in R&D and forming strategic partnerships, the company remains at the forefront of delivering health innovations that meet both current and future needs of the medical industry.
Earnings calendar coming soon. Subscribe to get notified when SGI reports next.
Get earnings alerts →